ArticleInternational journal of nanomedicine2018
Chemiplasmonics for high-throughput biosensors.
Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Laboratory-on-a-Smartphone.Analytical sciences : the international journal of the Japan Society for Analytical ChemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe sensitivity of ELISA for biomarker detection can be significantly increased by integrating fluorescence with plasmonics. In surface-plasmon-coupled emission, the fluorophore emission is generally enhanced through the so-called physical mechanism due to an increase in the local electric field. Despite its fairly high enhancement factors, the use of surface-plasmon-coupled emission for high-throughput and point-of-care applications is still hampered due to the need for expensive focusing optics and spectrometers.
methodsHere, we describe a new chemiplasmonic-sensing paradigm for enhanced emission through the molecular interactions between aromatic dyes and C
resultsA 20-fold enhancement in the emission from rhodamine B-labeled biomolecules can be readily elicited without quenching its red color emission. As a proof of concept, we demonstrate two model bioassays using: 1) the RhB-streptavidin and biotin complexes in which the dye was excited using an inexpensive laser pointer and the ensuing enhanced emission was recorded by a smartphone camera without the need for focusing optics and 2) high-throughput 96-well plate assay for a model antigen (rabbit immunoglobulin) that showed detection sensitivity as low as 6.6 pM.
conclusionOur results show clear evidence that chemiplasmonic sensors can be extended to detect biomarkers in a point-of-care setting through a smartphone in simple normal incidence geometry without the need for focusing optics. Furthermore, chemiplasmonic sensors also facilitate high-throughput screening of biomarkers in the conventional 96-well plate format with 10-20 times higher sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.